Eli Lilly has struck a $2.4 billion deal to buy Dice Therapeutics and its drug discovery and development platform for oral, small molecule therapies for immunological diseases. The big pharma is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback